MHRP The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense. CDR Jennifer Malia, DrPH U.S. Public Health Service Corps Military HIV Research Program (MHRP) Walter Reed Army Institute of Research (WRAIR) July 31, 2014 Clinical Evaluation of PIMA Point-of-Care Assay for Evaluation of CD4 Cell Counts Malia JA 1 , Giese RJ 1 , Manak M 2 , Bryant M 3 , Crawford K 2 , Lomabardi K 2 , Hale B 4 and Peel SA 1 1 Walter Reed Army Institute of Research, MHRP-WRAIR, Silver Spring, MD, 2 Henry Jackson Foundation, MHRP- HJF, Silver Spring, MD, USA; USA; 3 Howard University, Washington, DC, USA, 4 DoD HIV/AIDS Prevention Program, San Diego, CA, USA
Clinical Evaluation of PIMA Point-of-Care Assay for Evaluation of CD4 Cell Counts
Mar 21, 2016
CDR Jennifer Malia , DrPH U.S. Public Health Service Corps Military HIV Research Program (MHRP) Walter Reed Army Institute of Research (WRAIR) July 31, 2014. Clinical Evaluation of PIMA Point-of-Care Assay for Evaluation of CD4 Cell Counts. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
MH
RP
The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.
CDR Jennifer Malia, DrPHU.S. Public Health Service Corps
Military HIV Research Program (MHRP)Walter Reed Army Institute of Research (WRAIR)
July 31, 2014
Clinical Evaluation of PIMA Point-of-Care Assay for Evaluation of CD4 Cell Counts
Malia JA1, Giese RJ 1, Manak M2, Bryant M3, Crawford K2, Lomabardi K2, Hale B4 and Peel SA 1
1Walter Reed Army Institute of Research, MHRP-WRAIR, Silver Spring, MD, 2Henry Jackson Foundation, MHRP- HJF, Silver Spring, MD, USA; USA; 3Howard University, Washington, DC, USA, 4DoD HIV/AIDS Prevention Program, San Diego, CA, USA
MH
RP
Clinical Evaluation of PIMA Point-of-Care Assay for Evaluation of CD4 Cell Counts
Background CD4:
• Key predictive marker of disease progression • WHO recommends initiation of therapy when CD4+ drop below 500 cells/ml
Standard: • Complex testing, time consuming, highly trained personnel & expensive.
Benefits of POC• Fully automated, rapid, minimum training, well suited for testing at remote sites
Materials and Methods Prospective, random sampling
• 210 Adults HIV+ across spectrum of CD4 levels PIMA:
• Disposable cartridge with sealed reagents• Reference lab & clinic by nurse
Evaluation:• PIMA Venous and Fingerstick vs. BD FACSCanto II• At critical low and mid levels of CD4
MH
RP
RESULTSFig 2. Plot of CD4 counts as obtained by the Gold Standard FACS Canto vs that from PIMA Venous or PIMA Fingerstick.
Fig 3. Bland-Altman analysis of Mean vs Difference in CD4 counts between the FACS Canto and PIMA Venous or PIMA Fingerstick.
MH
RP
CONCLUSION
Venous Blood samples; Coefficient of Correlation >85.9%
Fingerstick assay excellent at low and high CD4+ ranges less reliable at the critical mid- range.
Minimal space and resources.
Suitable for use in resource limited settings.
We would like to acknowledge the Howard University General Clinical Research Center and their dedicated staff for their collaboration and efforts.
Thank You
Related Documents
